Retraction to: Oncogene (2016) 35, 241–250; doi:10.1038/onc.2015.78; published online 30 March 2015
The authors wish to retract this paper owing to the use of misidentified cell lines in the study. According to the description on the ATCC official website and reanalysis of the STR for cell line authentication, two misidentified glioblastoma cell lines, U251MG and U373MG, were used in this work. Based on recent literature (Torsvik et al. Cancer Med 2014; 3: 812–824), these two lines are thought to be cross-contaminated. Any data from misidentified or cross-contaminated cell lines are misleading—rendering conclusions incorrect.
G Xi, E Hayes, R Lewis, S Ichi, B Mania-Farnell, T Takao and CS Mayanil agreed to this retraction. K Shim, E Allender and T Tomita could not be reached to comment on the retraction.
Additional information
The online version of the original article can be found at 10.1038/onc.2015.78
About this article
Cite this article
Xi, G., Hayes, E., Lewis, R. et al. Retraction Note: CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro. Oncogene 35, 5576 (2016). https://doi.org/10.1038/onc.2016.64
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2016.64
